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Abstract
The long-standing promise for the application of engineered T lymphocytes to target and eradicate malignancy has
begun to be realized recently, with remarkable clinical success reported by a number of groups using Chimeric
Antigen Receptor –engineered T cells to target CD19-positive hematologic malignancies. In the September 2 issue
of Science Translational Medicine, Porter et al. present the clinical data and correlative analyses for 14 CLL patients
treated at the University of Pennsylvania under the pilot clinical trial recently completed at that institution. The
initial reports from this trial, published in 2011 documented robust clinical activity in a small cohort of treated
patients accompanied by logarithmic expansion, contraction, and long-term functional persistence of engineered
T cells, along with cytokine release syndrome as a side-effect of the treatment. In this latest report, updated data
are presented from the initial cohort of patients, as well as clinical and correlative data from the remainder of the
treated cohort. The robust clinical activity observed in the initial cohort continued to be observed in a subset of
the subsequently-treated patients, with molecular remissions documented in that subset; however, in the expanded
cohort a subset of partial and non-responding patients was also identified. Collectively, the results from this exciting
trial provide evidence to suggest that cellular immunotherapy using engineered T cells is a viable option for treating
CLL, reveal a likely requirement for robust in-vivo activation and persistence of engineered cells to effect complete
responses, and also highlight the need for a more complete mechanistic understanding of the immune- and
tumor- specific processes that define and dictate the success of this powerful treatment modality.
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Background
T lymphocytes, re-directed to target tumors through
molecular engineering and expression of recombinant
tumor-specific Chimeric Antigen Receptors (CAR) have
shown remarkable promise in clinical trials that target
hematological malignancies. Over the past 4 years, a
series of high-profile reports by different groups have
been published, demonstrating potent clinical activity
using this treatment paradigm, including eradication of
disease in late-stage patients with a variety of CD19-
positive leukemias [1–11]. Among these efforts, the ini-
tial publications of the group from the University of
Pennsylvania were particularly notable for the robust
and sustained clinical activity in late-stage treatment
refractory and relapsed CLL and ALL patients with
heavy disease burden, and also for the systematic and
mechanistically-informing biomarker strategy that was
applied in those studies and which identified potential
correlates for the observed clinical activities [1–3]. The
initial reports focused on a small cohort of patients
with late-stage disease, specifically 3 CLL patients and 2
pediatric ALL patients, each of whom had a strong anti-
tumor response. Notable observations in these initial re-
ports were the more than 4 log expansion of engineered
cells in vivo, followed by contraction and long-term func-
tional persistence of engineered cells, the deep molecular
remissions of disease, as well as the development of cyto-
kine release syndrome in each of the patients. For each of
the initial reports, the small cohort sizes precluded any
meaningful assessment of the clinical response rates, or a
robust understanding of correlates with efficacy.
Initial reports from the NCI and Memorial Sloan
Kettering groups confirmed the broader applicability of
this approach [5, 9] and also extended the applicability
of CAR-based targeting CD19+ malignancies to the
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setting of allogeneic transplantation [6] or as a bridge
toward allogeneic transplantation [10]. More recent re-
ports from the NCI group have also demonstrated the
ability to potently target ALL as well as to effectively
target additional CD19+ malignancies [7, 8]. Notable
correlative observations from each of these reports were
the apparent requirement for robust in-vivo expansion of
engineered T cells for clinical activity, the observation of
cytokine release syndromes as a correlate to clinical re-
sponse, and, in contrast with the reports from the UPenn
group, a lack of consistent long-term persistence of in-
fused cells.
A more mature data set for the UPenn ALL patient
cohort published earlier this year which included 25
pediatric and 5 adult patients demonstrated very high
clinical activity with a 90 % complete response rate and
78 % overall survival at 6 months, and a robust set of
correlative data to support the clinical observations [11].
In the September 2 issue of Science Translational Medi-
cine [12], Porter et al. describe the mature clinical data
and correlative analyses for the cohort of 14 CLL patients
treated at the University of Pennsylvania. These expanded
data further highlight and substantiate the potential for
CAR-engineered T cell-based therapy to mediate pro-
found activity in a subset of treatment refractory CLL
patients, and also provide further insights into corre-
lates of response post-infusion. Perhaps disappointingly
given that more than one-third of treated patients did
not respond to therapy, product- and patient- specific
attributes predictive of response were not reported in
these studies and remain undefined for CTL019 therapy
of patients with advanced CLL.
Main text
The expanded data set presented in this report enabled
initial estimates of overall response rates to CTL019 for
CLL patients, as well as the opportunity to begin to
understand patient and product correlates of response.
Estimated median survival for all treated patients was
29 months with 71 % overall survival at 18 months
(95 % confidence interval of 40.6-88.2 %). No patient or
tumor characteristics were identified that predicted or
correlated with response. Cytokine release syndrome se-
verity was associated with elevated peak levels of engi-
neered cells and statistically-significant elevations in IL6
and IL2RA. Three general patterns of clinical response
were observed in the 14 patient cohort: 4 patients
achieved a complete response (CR), an additional 4 pa-
tients achieved a partial response (PR), and 6 patients
did not respond (NR) to CTL019 treatment. For each of
the 4 CR patients, robust and greater than 4-log expan-
sion of CTL019 patients was observed, followed by
contraction and functional persistence of CTL019 cells.
Two of the CR patients were from the original cohort,
and both these patients remained MRD-negative over
4 years post-treatment, with CTL019 cells detectable by
Q-PCR and ongoing B cell aplasia. In the additional 2
CR patients CTL019 cells were also detectable in the
periphery for over 12 months, and each of these patients
remained MRD negative through the reporting interval.
Partial responders were characterized by a more com-
plex CTL019 expansion pattern: for 2 of the PR patients,
in vivo expansion was considerably less than the CR co-
hort (2-3 logs); however, 2 PR patients had considerable
expansion and persistence of CTL019 cells but did not
resolve disease, suggesting the existence of CLL resist-
ance mechanisms dominant to CTL019 activity; the
MRD analysis in these patients suggested incomplete
activity of CTL019 cells in marrow compared to the
periphery at early timepoints. Non responders were
characterized by lack of expansion, and no persistence,
underscoring the requirement for some degree of in
vivo functionality (proliferation, persistence) for
CTL019 efficacy. Disappointingly, obvious and relevant
questions about potential differences in product-specific
attributes that might correlate with in vivo functionality
were addressed only superficially in this report, with one
set of data suggesting a “polyfunctional” cytokine response
phenotype in all products, but not segregating these data
in terms of clinical response or in vivo expansion proper-
ties despite a broad distribution in the reported data.
Conclusions
The most notable conclusions from this report, which
represents the most comprehensive data set with regard
to CAR-based therapy in CLL are that i. CTL019 ther-
apy has the potential to mediate compete molecular re-
missions in CLL; ii. Complete and overall response
rates in CLL are significantly lower than those in ALL
patients, and iii. Robust in-vivo expansion and sus-
tained persistence of CTL019 cells are both likely re-
quirements for potent anti-CLL activity. A fundamental
and key outstanding question is whether the variability
in response to CTL019 treatment can be uniquely at-
tributed to a patient or a product specific property. The
more uniform response rates in ALL together with the
recently published observation that relapse mechanisms
in ALL but not CLL are associated with CD19-splice
variant selection [13] indicate that at least part of the
variability of response in CLL disease can be attributed
to in vivo disease-intrinsic mechanisms, although the
impact of manufacturing a product using lymphocytes
exposed to CLL vs ALL cells cannot be excluded. Efforts
to better understand how CLL (a “chronic”) vs ALL (an
“acute”) disease shape a T cell suppressive environment in
vivo and also shape the functional properties of manu-
factured CTL019 cells by epigenetic or otherwise
imprinted mechanisms are likely to be key to unlocking
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the full future potential of CTL019 therapy in CLL, by
pointing the way to combination strategies to more ef-
fectively target this disease.
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